Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment

MT Newswires Live

2024/12/06

Verrica Pharmaceuticals (VRCA) said Friday its development and commercialization partner Torii Pharmaceutical submitted a new drug application in Japan for TO-208, marketed as Ycanth in the US, to treat molluscum contagiosum skin infection.

The company said a phase 3 study in Japan of TO-208 in patients with molluscum contagiosum met its primary efficacy endpoint and showed that the drug's safety profile is consistent with prior studies in the US.

Verrica said it entered into an exclusive license agreement with Torii in 2021 for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan.

Verrica shares were more than 9% higher in recent premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2489725285"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489725285\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2489725285?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489725285","market":"sh","top_or_hot":-1,"title":"Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment","media":"MT Newswires Live","content":"<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday its development and commercialization partner Torii Pharmaceutical submitted a new drug application in Japan for TO-208, marketed as Ycanth in the US, to treat molluscum contagiosum skin infection.</p><p>The company said a phase 3 study in Japan of TO-208 in patients with molluscum contagiosum met its primary efficacy endpoint and showed that the drug's safety profile is consistent with prior studies in the US.</p><p>Verrica said it entered into an exclusive license agreement with Torii in 2021 for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan.</p><p>Verrica shares were more than 9% higher in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-06 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Verrica Pharmaceuticals (VRCA) said Friday its development and commercialization partner Torii Pharmaceutical submitted a new drug application in Japan for TO-208, marketed as Ycanth in the US, to treat molluscum contagiosum skin infection.</p><p>The company said a phase 3 study in Japan of TO-208 in patients with molluscum contagiosum met its primary efficacy endpoint and showed that the drug's safety profile is consistent with prior studies in the US.</p><p>Verrica said it entered into an exclusive license agreement with Torii in 2021 for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan.</p><p>Verrica shares were more than 9% higher in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489725285","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489725285","pubTimestamp":1733493470,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verrica Pharmaceuticals  said Friday its development and commercialization partner Torii Pharmaceutical submitted a new drug application in Japan for TO-208, marketed as Ycanth in the US, to treat molluscum contagiosum skin infection.The company said a phase 3 study in Japan of TO-208 in patients with molluscum contagiosum met its primary efficacy endpoint and showed that the drug's safety profile is consistent with prior studies in the US.Verrica said it entered into an exclusive license agreement with Torii in 2021 for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan.Verrica shares were more than 9% higher in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","VRCA":"Verrica Pharmaceuticals Inc."},"translate_title":"Verrica Pharmaceuticals合作伙伴Torii寻求日本批准皮肤感染治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Verrica Pharmaceuticals (VRCA) said Friday its development and commercialization partner Torii Pharmaceutical submitted a new drug application in Japan for TO-208, marketed as Ycanth in the US, to treat molluscum contagiosum skin infection.The company said a phase 3 study in Japan of TO-208 in patients with molluscum contagiosum met its primary efficacy endpoint and showed that the drug's safety profile is consistent with prior studies in the US.Verrica said it entered into an exclusive license agreement with Torii in 2021 for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan.Verrica shares were more than 9% higher in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}